BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34547870)

  • 21. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
    Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
    Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements.
    Yang H; Huang S; Zhu CY; Gao L; Zhu HY; Lv N; Jing Y; Yu L
    Med Sci Monit; 2016 Jul; 22():2315-23. PubMed ID: 27373985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
    Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
    Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
    Wang Y; Wu DP; Liu QF; Qin YZ; Wang JB; Xu LP; Liu YR; Zhu HH; Chen J; Dai M; Huang XJ
    Blood; 2014 Sep; 124(12):1880-6. PubMed ID: 25082877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality.
    Liu J; Han W; Cai X; Wang Z; Cao L; Hua H; Jia Z; Chao H; Lu X; Shen H
    Hematology; 2022 Dec; 27(1):565-574. PubMed ID: 35549661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with
    Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
    Shafik NF; Ibraheem D; Selim MM; Allam RM; Fathalla LA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e363-e375. PubMed ID: 34972661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
    Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy.
    Qin YZ; Xu LP; Chen H; Jiang Q; Wang Y; Jiang H; Zhang XH; Han W; Chen YH; Wang FR; Wang JZ; Zhu HH; Liu YR; Jiang B; Liu KY; Huang XJ
    Leuk Lymphoma; 2015; 56(11):3116-23. PubMed ID: 25804769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
    Zhao T; Zhang Y; Yang S; Bao L; Wang J; Jiang H; Zhu H; Jia J; Lu J; Jiang B; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):89-94. PubMed ID: 25778880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.